Abstract:Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide. EBV is also the primary cause of infectious mononucleosis, and up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis. In addition, EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. An EBV prophylactic vaccine that induces neutralizing antibodies holds great promise for prevention of EBV associated diseases. EBV envelope proteins including gH/gL, gB and gp350 play key roles in EBV entry and infection of target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells and markedly decrease EBV titers in the peripheral blood of humanized mice challenged with lethal dose EBV. Recent studies demonstrated that immunization with the combination of gH/gL, gB and/or gp350 induced markedly increased synergistic EBV neutralizing activity compared to immunization with individual proteins. As previous clinical trials focused on gp350 alone were partially successful, the inclusion of gH/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development. Therapeutic EBV vaccines have also been tested clinically with encouraging results. Immunization with various vaccine platforms expressing the EBV latent proteins EBNA1, LMP1, and/or LMP2 promoted specific CD4+ and CD8+ cytotoxic responses with anti-tumor activity. The addition of EBV envelope proteins gH/gL, gB and gp350 has the potential to increase the efficacy of a therapeutic EBV vaccine. The immune system plays a critical role in the control of tumors, and immune cell therapy has emerged as a promising treatment of cancers. Adoptive T-cell therapy has been successfully used in the prevention and treatment of post-transplant lymphoproliferative disorder. Chimeric antigen receptor T cell therapy and T cell receptor engineered T cell therapy targeting EBV latent proteins LMP1, LMP2 and/or EBNA1 have been in development, with the goal to increase the specificity and efficacy of treatment of EBV associated cancers.

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV

Immunization with a Self-Assembled Nanoparticle Vaccine Elicits Potent Neutralizing Antibody Responses against EBV Infection

Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice

A Cocktail Nanovaccine Targeting Key Entry Glycoproteins Elicits High Neutralizing Antibody Levels Against EBV Infection

A Novel Vaccine Candidate Based on Chimeric Virus-Like Particle Displaying Multiple Conserved Epitope Peptides Induced Neutralizing Antibodies Against EBV Infection

Neutralizing Antibodies Against EBV Gp42 Show Potent in Vivo Protection and Define Novel Epitopes.

A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge In Vivo

An Insect Cell-Derived Extracellular Vesicle-Based Gb Vaccine Elicits Robust Adaptive Immune Responses Against Epstein-Barr Virus

A Potent and Protective Human Neutralizing Antibody Targeting a Novel Vulnerable Site of Epstein-Barr Virus

Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge

Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region

Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection

Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells

A Novel High Throughput Assay to Quantify Epstein-Barr Virus Neutralizing Antibody Activity Against B-cell and Epithelial Cell Infections for Vaccine and Therapeutic Developments.

A Large-Scale Population-Based Study Reveals That Gp42-Igg Antibody is Protective Against Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases